Search

Your search keyword '"Gay, Cynthia L"' showing total 284 results

Search Constraints

Start Over You searched for: Author "Gay, Cynthia L" Remove constraint Author: "Gay, Cynthia L"
284 results on '"Gay, Cynthia L"'

Search Results

1. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

2. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial

3. Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

4. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

5. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

6. Risk of COVID-19 after natural infection or vaccination

7. The HIV-1 latent reservoir is largely sensitive to circulating T cells.

8. HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy

10. Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy Indicating A Lack Of Ongoing Viral Replication

11. COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials

12. Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.

14. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy

16. HIVepsilon-seq—scalable characterization of intact persistent proviral HIV reservoirs in women

17. Risk of COVID-19 after natural infection or vaccination

18. Combined noncanonical NF-[kappa]B agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo

19. Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.

22. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

23. Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico

27. T cells establish and maintain CNS viral infection in HIV-infected humanized mice

28. A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots

29. NVX-CoV2373 Efficacy in Preventing SARS-CoV-2 Infection in Adolescents

31. 1253. Acceptability and feasibility of long-acting injectable antiretroviral therapy for persons who inject drugs in Vietnam: using the Consolidated Framework on Implementation Research to identify determinants and inform implementation strategies

33. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

36. Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial

37. Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A qualitative study

40. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells

41. Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo

49. Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population

50. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat

Catalog

Books, media, physical & digital resources